Abstract
Glucose addiction is observed in cancer and other diseases that are associated with hyperproliferation. The development of compounds that restrict glucose supply and decrease glycolysis has great potential for the development of new therapeutic approaches. Addressing facilitative glucose transporters (GLUTs), which are often upregulated in glucose-dependent cells, is therefore of particular interest. This article reviews a selection of potent, isoform-selective GLUT inhibitors and their biological characterization. Potential therapeutic applications of GLUT inhibitors in oncology and other diseases that are linked to glucose addiction are discussed.
Keywords:
GLUT inhibitors; antitumor agents; cancer; drug discovery; metabolism.
© 2019 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Glucose / antagonists & inhibitors
-
Glucose / metabolism
-
Glucose Transporter Type 1 / antagonists & inhibitors*
-
Glucose Transporter Type 1 / chemistry
-
Glucose Transporter Type 2 / antagonists & inhibitors*
-
Glucose Transporter Type 2 / chemistry
-
Glucose Transporter Type 3 / antagonists & inhibitors*
-
Glucose Transporter Type 3 / chemistry
-
Glucose Transporter Type 4 / antagonists & inhibitors*
-
Glucose Transporter Type 4 / chemistry
-
Humans
-
Models, Molecular
-
Molecular Structure
-
Small Molecule Libraries / chemistry
-
Small Molecule Libraries / pharmacology*
Substances
-
Glucose Transporter Type 1
-
Glucose Transporter Type 2
-
Glucose Transporter Type 3
-
Glucose Transporter Type 4
-
SLC2A1 protein, human
-
SLC2A2 protein, human
-
SLC2A3 protein, human
-
SLC2A4 protein, human
-
Small Molecule Libraries
-
Glucose